Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

ClinicalTrials.gov ID: NCT03794583

Public ClinicalTrials.gov record NCT03794583. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension Study of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623). This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).

Study identification

NCT ID
NCT03794583
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
United Therapeutics
Industry
Enrollment
41 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 21, 2018 (Actual)
Primary completion
Nov 29, 2022 (Actual)
Completion
Nov 29, 2022 (Actual)
Last update posted
May 27, 2026

2018 – 2022

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
The University of Alabama at Birmingham Birmingham Alabama 35294 —
University of California Davis Medical Center Sacramento California 95817 —
St. Francis Sleep Allergy & Lung Institute Clearwater Florida 33765 —
St. Vincent's Lung, Sleep, and Criticial Care Specialists Jacksonville Florida 32204 —
Mayo Clinic - Jacksonville Jacksonville Florida 32224 —
University of Miami Hospital Miami Florida 33136 —
Pulmonary & Critical Care of Atlanta Atlanta Georgia 30342 —
Georgia Clinical Research Austell Georgia 30106 —
University of Illinois Medical Center Chicago Illinois 60612 —
St. Vincent Medical Group, Inc. Indianapolis Indiana 46260 —
Kentuckiana Pulmonary Associates Louisville Kentucky 40202 —
University of Maryland Medical Center Baltimore Maryland 21201 —
Brigham and Women's Hospital Boston Massachusetts 02115 —
Spectrum Health Grand Rapids Michigan 49546 —
Memorial Hospital at Gulfport Gulfport Mississippi 39501 —
Albany Medical Center Albany New York 12208 —
Mount Sinai Medical Center New York New York 10029 —
University of Rochester Medical Center Rochester New York 14623 —
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 —
The Carl and Edyth Lindner Research Center at The Christ Hospital Cincinnati Ohio 45219 —
Cleveland Clinic Cleveland Ohio 44195 —
Allegheny General Hospital Pittsburgh Pennsylvania 15212 —
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213 —
Medical University of South Carolina Charleston South Carolina 29425 —
Inova Fairfax Hospital Falls Church Virginia 22042 —
Pulmonary Associates of Richmond, Inc. Richmond Virginia 23230 —
Carilion Clinic Roanoke Virginia 24014 —
University of Wisconsin School of Medicine and Public Health Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03794583, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 27, 2026 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03794583 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →